Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)
4.9500
0.00 (0.00%)
Quantum Biopharma Ltd. is a biotechnology company focused on developing innovative therapies and treatments for a range of diseases, leveraging advanced biopharmaceutical technologies
The company specializes in creating novel drugs and biologics aimed at improving patient outcomes and addressing unmet medical needs in various therapeutic areas. Through a combination of cutting-edge research and strategic partnerships, Quantum Biopharma is actively engaged in bringing its proprietary products from the lab to clinical trials, with the ultimate goal of enhancing healthcare options and improving the quality of life for patients worldwide.
The company has attracted heavy attention after its dietary supplement, Unbuzzd, showed that it can reduce blood alcohol concentration rapidly in a clinical trial.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Quantum BioPharma shares are surging Thursday after its licensee, Celly Nutrition, engaged a New York investment bank to raise up to $10 million and explore a potential U.S. initial public offering.
The company said it also led to a 67% reduction in headache severity at four hours and continued to ease cognitive and physical impairment up to eight hours after consumption.
Shares of Quantum BioPharma Ltd. (NASDAQQNTM) are soaring more than 70% on Tuesday after the company announced positive clinical trial results for its dietary supplement, unbuzzd, which accelerates the reduction of blood alcohol concentration.
Quantum BioPharma Ltd (NASDAQQNTM) shares are rising Tuesday after the company announced positive clinical trial results for its unbuzzd dietary supplement.
